Imprimis Pharmaceuticals Expands Distribution of its Proprietary Ophthalmic and Urologic Formulations into Texas and Virginia
Thursday, August 06, 2015
Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, has expanded the availability of its proprietary ophthalmic and urologic compounded formulations to physicians and patients in Texas. The Company's expansion into the Lone Star State resulted from its recent acquisition of JT Pharmacy, Inc., d/b/a Central Allen Pharmacy, a compounding pharmacy located outside of Dallas. Imprimis' New Jersey compounding pharmacy also received licenses to dispense in Texas and Virginia.
Mark L. Baum, CEO of Imprimis, stated, "The acquisition of our third compounding pharmacy and licensure in Texas represents an important milestone for our company and for me personally because I was born and raised in Texas and have a special appreciation for its size and dynamism. Texas has experienced tremendous growth over the past several years due to its attractive tax climate, diverse economy, low unemployment, highly skilled and educated work force, affordable housing and several large and growing cities such as Dallas, Austin, San Antonio and Houston. We are confident that our investment in Texas will blossom just like a field of beautiful bluebonnets."
Mr. Baum added, "In order to take advantage of these opportunities, we have hired regional business directors in both ophthalmology and urology specifically to cover this market. We have already begun to reach out to dozens of ophthalmology practices that have expressed interest in implementing our Dropless Therapy™ in their practices. We are also looking forward to servicing the more than 800 urologists located in Texas and specifically the large patient populations that can benefit from our patented HLA compounded formulation, which is prescribed by physicians for the treatment of symptoms associated with interstitial cystitis, and our lyophilized Tri-Mix formulations for the treatment of erectile dysfunction."
imprimispharma.investorroom.com
